SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 30, 2011
ALEXION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
352 Knotter Drive, Cheshire, Connecticut 06410
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (203) 272-2596
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On May 30, 2011, Alexion Pharma Germany GmbH, a subsidiary of the registrant Alexion Pharmaceuticals, Inc., announced that, in view of the growing epidemic of Enterohaemorrhagic Escherichia coli (EHEC) infections in Germany, it initiated an eculizumab access program in response to requests from physicians who are treating patients with Shiga-toxin producing E. coli haemolytic uremic syndrome (STEC-HUS), a potentially life-threatening outcome of EHEC. Alexion is providing these physicians with eculizumab (Soliris®) at no charge and is also collaborating with them to review related scientific and medical information to support the best treatment options for patients with STEC-HUS. Eculizumab is not approved for the treatment of STEC-HUS in Germany or elsewhere.
An English translation of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.